Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Ayalew Tefferi, Chandra Hutchens, Antoine N. Saliba, Giuseppe Gaetano Loscocco, Kebede Begna, William J. Hogan, Kaaren K. Reichard, Animesh D. Pardanani, Sima Bhatt, William Savage, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2024-209070

Published: 2024

Journal Articles

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Giuseppe Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Omer Karrar, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Natasha Szuber, Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi, Cinthya Zepeda Mendoza, Kaaren K. Reichard, Rong He, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2024-193373

Published: 2024

Journal Articles

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Mrinal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2024-193907

Published: 2024

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren K. Reichard, Cinthya Zepeda Mendoza, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2024-193120

Published: 2024

Journal Articles

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

Mahlet Siraga, Maymona Abdelmagid, Moazah Iftikhar, Masooma S Rana, Kebede Begna, Kaaren K. Reichard, Rong He, Cinthya Zepeda Mendoza, Ronald S Go, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2024-198840

Published: 2024

Journal Articles

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Ayalew Tefferi, Saubia Fathima, Ali Khalid Alsugair, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Hassan B Alkhateeb, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2024-207736

Published: 2024

Journal Articles

PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

Saubia Fathima, Ali Alsugair, Anuya A. Natu, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Kaaren K. Reichard, Rong He, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 4586.

https://doi.org/10.1182/blood-2024-206007

Published: 2024

Journal Articles

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Blood (2024) 144 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2024-204334

Published: 2024

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

Zhuoer Xie, Kristen McCullough, Terra L Lasho, Jenna A. Fernandez, Christy M Finke, Michelle Renee Amundson, Betsy LaPlant, Abhishek Mangaokar, Naseema Gangat, Kaaren K. Reichard, Michelle Ann Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2023-186595

Published: 2023

Journal Articles

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Maymona Abdelmagid, Jeanne Palmer, James M. Foran, Aref Al-Kali, Omer Karrar, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2023-180235

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Naseema Gangat, Omer Karrar, Maymona Abdelmagid, Moazah Iftikhar, Kaaren K. Reichard, Natasha Szuber, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2023-179596

Published: 2023

Journal Articles

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

Abhishek A Mangaonkar, Terra L Lasho, Justin Boysen, Christy M Finke, Jenna A. Fernandez, Jose. C. Villasboas, Christopher Dean, Alejandro Ferrer, Moritz Binder, Liguo Wang, Jeong-Heon Lee, Kaaren K. Reichard, Mrinal M. Patnaik

Blood (2023) 142 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2023-186856

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Animesh Pardanani, Ayalew Tefferi, Amritpal Singh, Aref Al-Kali, Mrinal M. Patnaik, William J. Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen

Blood (2022) 140 (Supplement 1): 6872–6873.

https://doi.org/10.1182/blood-2022-167720

Published: 2022

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Zhuoer Xie, Kristen McCullough, Terra Lasho, Jenna A. Fernandez, Christy Finke, Michelle Renee Amundson, Betsy Laplant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle A Elliott, Thomas E. Witzig, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 2893–2894.

https://doi.org/10.1182/blood-2022-165163

Published: 2022

NARROW

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias

ASXL1 Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Sodium-Glucose Co-Transporter-2 Inhibitor Use in the Setting of Myeloproliferative Neoplasms: Impact on Hemoglobin/Hematocrit Levels and Thrombosis Risk

Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only